Clasado Biosciences has confirmed its attendance at the IPA World Congress + Probiota 2026, taking place 11-13 February in Dublin, Ireland.
Representing Clasado during the three-day event will be CEO Per Rehné, Director of Business Development Annika Malmros, and Vice President of Sales & Marketing Marcelo Durante. During the event, the team will be available for meetings with attendees looking to harness the power of prebiotics in 2026 and beyond.
Organised by NutraIngredients, Probiota unites the worlds of microbiome science and business, bringing together industry leaders to explore the latest developments in the biotics category, including prebiotics, probiotics, and synbiotics. The event will feature dynamic learning sessions, Scientific Frontiers presentations and the Probiota Pioneers competition, highlighting innovative early-stage companies driving the future of microbiome innovation.
Bimuno® GOS delivers clinically proven benefits across multiple health areas, from supporting gastrointestinal health through reduced bloating and improved bowel regularity, to supporting immune health and the gut-brain axis. The multi award-winning ingredient offers formulators versatility, being suitable for applications across functional foods, beverages, supplements and sports nutrition.
Marcelo commented: “Probiota consistently delivers valuable insights into emerging areas of microbiome science, as well as strong commercial opportunity for attendees. As the developers behind Bimuno® GOS, the most widely studied prebiotic in its category, engaging with the research and commercial microbiome community is a fantastic way to share ideas and come together and inspire innovation. We’re looking forward to connecting with formulators and brand owners who are keen on developing scientifically substantiated gut health solutions across diverse health areas, from gastrointestinal health to immunity and brain health.”
Leading the way in prebiotic science, Clasado continues to advance the understanding of prebiotics through rigorous clinical research.
With over 130 scientific publications, including more than 20 clinical studies, Bimuno GOS is the most widely studied prebiotic galactooligosaccharide on the market, making Probiota an ideal platform for the team to discuss the latest prebiotic gut health science with the global microbiome community. Those interested in connecting with the Clasado team at Probiota 2026 are encouraged to reach out and arrange a meeting at their convenience.
To learn more about the market-leading portfolio of science behind Bimuno GOS, please click here.
